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OBJECTIVE—The expansion of adipose tissue is linked to the
development of its vasculature. However, the regulation of
adipose tissue angiogenesis in humans has not been extensively
studied. Our aim was to compare the angiogenesis associated
with subcutaneous adipose tissue (SAT) and visceral adipose
tissue (VAT) from the same obese patients in an in vivo model.
RESEARCH DESIGN AND METHODS—Adipose tissue sam-
ples from visceral (VAT) and subcutaneous (SAT) sites, obtained
from 36 obese patients (mean BMI 46.5 kg/m
2) during bariatric
surgery, were layered on chick chorioallantoïc membrane (CAM).
RESULTS—Both SAT and VAT expressed angiogenic factors
without signiﬁcant difference for vascular endothelial growth
factor (VEGF) expression. Adipose tissue layered on CAM stim-
ulated angiogenesis. Angiogenic stimulation was macroscopi-
cally detectable, with engulfment of the samples, in 39% and was
evidenced by angiography in 59% of the samples. A connection
between CAM and adipose tissue vessels was evidenced by
immunohistochemistry, with recruitment of both avian and hu-
man endothelial cells. The angiogenic potency of adipose tissue
was not related to its localization (with an angiogenic stimulation
in 60% of SAT samples and 61% of VAT samples) or to adipocyte
size or inﬂammatory inﬁltrate assessed in adipose samples
before the graft on CAM. Stimulation of angiogenesis by adipose
tissue was nearly abolished by bevacizumab, which speciﬁcally
targets human VEGF.
CONCLUSIONS—We have established a model to study the
regulation of angiogenesis by human adipose tissue. This model
highlighted the role of VEGF in angiogenesis in both SAT and
VAT. Diabetes 57:3247–3257, 2008
A
dipose tissue retains substantial plasticity in
adulthood. Its mass can increase or decrease
up to 10-fold throughout life. The prevalence of
obesity has doubled over the last 20 years, and
current pharmacotherapy is relatively ineffective in main-
taining long-term weight loss (1). A better understanding
of the development of adipose tissue is required to identify
new therapeutic approaches to obesity.
Angiogenesis and adipogenesis are linked functionally
(2). During embryogenesis, the development of adipose
tissue and its vascularization are temporally and spatially
related (3). In animal models of genetic and induced
obesity, the expansion of adipose tissue is associated with
active angiogenesis, whereas inhibition of angiogenesis
prevents adipose tissue development (4–6). Angiogenesis
induced by adipose cells in animal models increases along
with adipocyte differentiation (7–9), and conversely, an-
giogenic factors, such as vascular endothelial growth
factor (VEGF), can modulate adipocyte differentiation (8).
The cross-talk between adipocytes and endothelial cells
involves numerous paracrine factors associated with an-
giogenesis and/or adipose tissue differentiation. It also
involves direct cell-to-cell interactions, and it should be
noted that human adipose tissue–derived stem cells can
differentiate into either adipocyte or endothelial cells
(10–12).
Numerous studies have shown that adipose tissue can
stimulate angiogenesis in physiological models, such as
the chick chorioallantoïc membrane (CAM) and the rabbit
cornea (7,13,14), or in pathophysiological models, such as
wound healing and revascularization of ischemic tissues
(2,11,12,15–17). Adipose tissue produces several factors
involved in angiogenesis, and local or circulating levels
of tumor necrosis factor- (TNF-), VEGF, plasminogen
activator inhibitor-1 (PAI-1), and angiopoïetin-2 are in-
creased in animal and human obesity (2,18–20). Con-
versely, factors involved in adipocyte regulation, such as
leptin, adiponectin, visfatin, or peroxisome proliferator–
activated receptor  (PPAR), for example (2,3,8,21–24),
also regulate angiogenesis.
However, there have been few studies of the mecha-
nisms of stimulation of adipose tissue angiogenesis in
obesity. The characteristics of adipose tissue that could
inﬂuence angiogenesis in humans, such as whether the
tissue is of subcutaneous or visceral origin, the presence
of inﬁltrating macrophages, and the proﬁle of expression
of angiogenic factors are still unknown. Very few studies
(8,24,25) have tried to inhibit angiogenic factors to identify
their role in adipose tissue angiogenesis.
Our main objectives were to compare the angiogenic
potency of subcutaneous adipose tissue (SAT) and vis-
ceral adipose tissue (VAT) from obese patients and to
assess whether the characteristics of adipose tissue and
the phenotype of the patients inﬂuence angiogenesis asso-
ciated with adipose tissue.
RESEARCH DESIGN AND METHODS
Thirty-six consecutive patients attending our institution for bariatric surgery
were included in the study between October 2005 and June 2007. The bariatric
surgery was performed in accordance with the recommendations of interna-
tional committees and consensus conferences, as previously described (26).
Informed consent was required and obtained before inclusion, and the local
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DIABETES, VOL. 57, DECEMBER 2008 3247ethics committee approved the protocol. All obese patients underwent routine
physical examination and systematic fasting biological analyses (26) before
surgery (mean 3  2 months). A two-point assessment of fasting plasma
insulin and blood glucose concentrations was performed only in nondiabetic
patients to calculate the homeostasis minimal assessment (HOMA) index of
insulin resistance. Treatments for hypertension, diabetes, dyslipidemia, and
obstructive sleep apnea were systematically recorded.
Adipose tissues samples. SAT from abdominal wall and VAT from an
omental site were collected during the surgical procedure and were immedi-
ately transported at 20°C to the laboratory in Dulbecco’s modiﬁed Eagle’s
medium (DMEM)/F12 (Invitrogen, Cergy pontoise, France) containing 2% BSA
(Sigma, Saint-quentin Fallavier, France). Aliquots of the samples were ﬁxed in
4% paraformaldehyde (PFA) or frozen in liquid nitrogen and stored at 80°C.
The remaining samples were rinsed in DMEM/F12 without BSA, centrifuged
for 30 s at 250g to separate from erythrocytes (11), cut in small pieces of 3–50
mg, and placed onto the CAM (see below). Adipose tissue fractions were
isolated as previously described (11).
In vivo angiogenesis. Fertilized White Leghorn chick eggs were incubated as
previously described (27). SAT and VAT samples were layered on the chick or
quail CAM after 8 days of incubation. One to ﬁve samples were placed on each
CAM. Angiogenesis was quantiﬁed on CAM 5–7 days later (days 13–15 of
incubation) with a MZ FLIII Leica stereomicroscope (8). Angiographies
were performed as described previously (28). For VEGF inhibition, PTK
787/ZK222584 (Novartis Pharma, Basel, Switzerland), an inhibitor of the
tyrosine kinase of the VEGF receptor active in human and chicken (27), was
added to the adipose tissue samples at 200 mol/l twice daily for 48 h.
Bevacizumab (Genentech, San Francisco, CA), a monoclonal antibody that
speciﬁcally inhibits human VEGF with no cross-reaction with other species
(29), was added at 320 g/ml with the same protocol.
Histochemistry. For immunohistochemistry, the primary antibodies used are
detailed below. Staining was performed as previously described (28) except
for the quail hematopoietic and endothelial cells (QH1) antibody for which the
peroxidase-linked secondary antibody (1/200) was revealed by incubation
with HistoGreen (AbCys, Paris, France) (30).
Freshly collected adipose tissue samples were ﬁxed for5hi n4 %P F Aa n d
embedded in parafﬁn (27). Samples were stained with 0.2% toluidine blue to
measure surface areas of individual adipocytes. The vascular density was
measured on slides that were stained with anti–von Willebrand antibody
(1:600; Dako, Trappes, France). The inﬂammatory inﬁltrate was assessed
using either anti-CD45 or anti-CD68 antibodies (1:50; Dako). Adipocyte area
and vessel density were determined on at least three ﬁelds of 2,059  1,544
m
2, and CD45 and CD68 were measured on at least ﬁve ﬁelds of 1,029  772
m
2, using the IPLab program (Scanalytics, Fairfax, VA). The coefﬁcient of
correlation between the density of CD45
 and CD68
 cells was r  0.86 (P 	
0.0001).
Adipose tissue samples that were grafted on CAM were ﬁxed for2hi n4 %
PFA, embedded in parafﬁn, and stained with hematoxylin-eosin for morpho-
logical studies. Chick erythrocytes were stained with an antibody speciﬁc for
chicken (1:1,500; QMS, Biovalley, Marne la valle ´e, France). Human endothelial
cells were detected by staining with an anti-CD34 primary antibody (1/100;
Immunotech, Marseille, France). For double staining of human and quail
endothelial cells, adipose tissue samples grafted on quail CAM were stained
with anti-CD34 antibody and then incubated with an anti-QH1 antibody (1/2)
(30).
The level of hypoxia within adipose tissue samples that were grafted on
CAM was assessed by Hypoxyprobe (Chemicon, Millipore, Molsheim, France)
according to the manufacturer’s instructions. Hypoxyprobe was incubated for
3ha t2 1 %O 2, either layered in a siliconized ring around adipose tissue
samples (1 mg/ml) or injected intravenously (100 l at 10 mg/ml). Bromo-
deoxy-uridine (BrdU) incorporation was performed with the BrdU in situ
detection kit II (BD Biosciences Pharmingen, San Diego, CA) as previously
described (27).
Chick cells inside human adipose tissue samples were stained after
injection of avian replication competent avian sarcoma-leucosis (RCAS)
virus–green ﬂuorescent protein (GFP) (31) into the vitellin anterior vein of the
embryo on day 3 of incubation in a volume of 1–2 l. RCAS-infected CAM
vessels around adipose tissue were observed on day 15 of incubation under
ﬂuorescent light. Samples were then stained with a biotinylated anti-GFP
antibody (1:200; Vector, Burlingame, CA).
Real-time quantitative RT-PCR. Angiogenic factor mRNAs were quantiﬁed
by real-time quantitative RT-PCR. Total RNA was extracted with TriZol (2.5
ml/500 mg tissue) and puriﬁed using the RNeasy Lipid Tissue kit (Qiagen,
Valencia, CA) according to the manufacturer’s instructions (12). Angiogenic
factor mRNAs were assayed with RT
2 proﬁler PCR array plates and RT2
real-time SYBR Green ﬂuorescein PCR master mix (Bioscience, Frederick,
MD) following the manufacturer’s instructions. SYBR green ﬂuorescence was
quantiﬁed with icycler (Bio-Rad).
We selected the genes of angiogenic factors previously implicated in
adipose tissue angiogenesis (2,8,9,18,32,33) and factors that were differentially
expressed in VAT and SAT in our preliminary experiments. Five genes of
which the expression increases with adipocyte differentiation were also
included as controls. The genes were analyzed in triplicate, and results are
reported relative to the values for three housekeeping genes (RPL13A,
GAPDH, and actin B). Using this method, one can compare different samples
for the expression of a given gene but not different genes in the same sample.
The difference of 
Ct (Ct for the gene  Ct for the mean of three housekeep-
ing genes) between SAT and VAT for each gene of interest is expressed as fold
difference (2

Ct2
Ct1). The difference of mRNA expression between SAT and
VAT was considered signiﬁcant when fold difference was 2 (34).
Statistical analysis. Data are expressed as means  SD or SE as indicated
for continuous data and percentages for categorical data. They were analyzed
by ANOVA and regression analysis. We tested that ﬁrst and second moments
of models are correctly speciﬁed (homoscedasticity). Statistical analysis used
the SAS System Package version 8.02 (SAS Institute, Cary, NC). All tests of
signiﬁcance were two-tailed. Differences were considered signiﬁcant when the
P value was 	0.05. Associations were ﬁrst considered statistically signiﬁcant
at a two-tailed value of 0.05.
RESULTS
Characterization of VAT and SAT. The main clinical
characteristics of the patients are available in Table 1.
These patients (men/women  7/29) presented with se-
vere obesity (BMI 46.5  7.2 kg/m
2), and 86% had severe
comorbidities.
Histological characteristics of both abdominal SAT and
omental VAT before graft are illustrated in Fig. 1. The
average adipocyte area of SAT exceeded that of VAT (Fig.
1A). The vessel density (Fig. 1B) was higher in VAT than in
SAT. However, when normalized to the mature adipocyte
density, the vessel density was similar in VAT and SAT
TABLE 1
Clinical characteristics of the patients
n 36
Men/women 7/29
Age (years) 46  10
Weight (kg) 127  23
BMI (kg/m
2) 46.5  7.2
Waist circumference (cm) 126  16
Systolic blood pressure (mmHg) 131  13
Diastolic blood pressure (mmHg) 68  13
Apnea-hypopnea index (n/h) 32  25
Current smokers (n %
) 9 (25)
Women with oral contraceptive 8 (28)
Menopause (n %
) 6 (21)
Patients receiving treatment for
Hypertension (n %
) 17 (47)
Beta-blocker 6
Angiotensin inhibitors 9
Calcium channel blockers 3
Diuretics 7
Diabetes (n %
) 8 (22)
Metformin 5
Sulfamides 4
Thiazolidinediones 1
Insulin 2
Dyslipidemia (n %
) 7 (19)
Statins 5
Fibrates 2
Obstructive sleep apnea (n %
) 25 (69)
Continuous positive airway pressure 25
Asthma (n %
) 5 (14)
Data are means  SD or n (%) of patients. Apnea-hypopnea index
10 indicates obstructive sleep apnea syndrome. Blood pressure
was measured at rest with an automatic device. Apnea-hypopnea
index was measured by ambulatory polysomnography.
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 and
CD68
 cells, were detected in VAT than in SAT (Fig. 1C).
After normalization for the adipocyte density, the differ-
ence persisted in paired t tests for CD68
 cells (2.13  1.17
vs. 1.87  1.05 n/adipocyte for VAT and SAT, respectively;
P 	 0. 05).
mRNA of genes involved in angiogenesis. Figure 2
summarizes the semiquantitative assessment of the level
of mRNA expression of a set of genes involved in the
regulation of angiogenesis and that of ﬁve genes of adipo-
cyte differentiation in VAT and SAT samples from 10 of the
obese subjects. Details are available in an online appendix
at http://dx.doi.org/10.2337/db07-1812 (supplementary Ta-
ble). There was no difference in the expression of markers
of adipocyte differentiation, according to the visceral or
subcutaneous origin, except for leptin, which was ex-
pressed at a higher level in SAT than in VAT (Fig. 2), as
expected (33). The expression level of the genes of growth
factors involved in adipose tissue angiogenesis, including
VEGF-A and -C, was similar in SAT and VAT. Also, the
expression of cytokines, including TNF- and interleukin
6( IL-6), did not signiﬁcantly differ between VAT and SAT.
However, several genes were expressed more strongly in
VAT than in SAT: the chemokine CXCL6, the cyclooxygen-
ase PTGS1, heparanase, and ﬁbroblast growth factor
(FGF-1). Conversely, mRNA of the metalloproteases
MMP9 and aminopeptidase N were more abundant in SAT
than in VAT (Fig. 2).
Preliminary results of expression of the same set of
genes in adipose tissue fractions, i.e., mature adipocytes
and stromavascular fraction from two patients, are shown
in the online appendix (supplementary Table). One impor-
tant ﬁnding was that both VEGF-A and -C were expressed
at similar levels in stromavascular fraction and mature
adipocyte fractions.
In vivo angiogenesis. Adipose tissue samples were col-
lected from 29 of the 36 patients and were layered on CAM.
They induced a strong angiogenic response (Fig. 3). A
macroscopic angiogenic response of the CAM, including
engulfment of the samples with the formation of a dense
surrounding vascular network (Fig. 3A), was observed in
39% of the adipose tissue samples from the 29 obese
subjects after 7 days (n  913 samples). Angiogenic
stimulation by adipose tissue from 11 of the obese subjects
was angiographically assessed: vascular attraction (Fig.
3C) or engulfment (Fig. 3D), scored as positive responses,
was observed in 59% of the samples (n  117).
A B
100 µm 100 µm
C
100 µm
Adipocyte size 
(µm²)
Inflammatory cells
(n/1000 µm²)
(n =35) SAT                VAT               p
2399  ± ± 815 2078  ± 630 < 0.001
Vessel density
(n/ 1000 µm²)
(n/adipocyte)
0.28  ± 0.16
0.61  ± 0.34
0.35  ± 0.16
0.71  ± 0.40
0.004
0.105
0.73  ± 0.37
0.74  ± 0.42
< 0.001
< 0.001
0.94  ± 0.50
0.98  ± 0.51
CD45  
CD68
D
FIG. 1. Histological characteristics of SAT and VAT. Slides of adipose tissue samples were stained with toluidine blue for the measurement of
adipocyte area (A), anti–von Willebrand antibody for the evaluation of vessel density (magniﬁcation 50) (B), and anti-CD45 (left) and
anti-CD68 (right) antibodies for the quantiﬁcation of inﬂammatory inﬁltrate (magniﬁcation 100) (C). D: Results obtained in 35 patients (n)
are expressed as means  SD and were compared by paired t tests. All signiﬁcant differences between SAT and VAT were also signiﬁcant in
unpaired t tests (P < 0.05). (Please see http://dx.doi.org/10.2337/db07-1812 for a high-quality digital representation of this ﬁgure.)
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After 7 days of incubation on CAM, adipose tissue samples
that had induced angiogenic response were viable and had
a normal histological aspect (Fig. 4A). In contrast, samples
that did not induce angiogenic response were dry and ﬂat
and showed degenerative features (Fig. 4B). No evidence
of hypoxia was detected between days 9 and 15 within the
successful adipose tissue grafts, after an intravenous Hy-
poxyprobe injection (Fig. 4C), or after local delivery (data
not shown).
Vascular connections between the vascular network of
the CAM and that of viable adipose tissue grafts were
evidenced ﬁrst by the detection of chick erythrocytes
within human adipose tissue (Fig. 4D). In a second exper-
iment, BrdU was injected into a vein of the CAM, at
distance from the adipose tissue grafts. BrdU
 cells were
detected inside the grafts, conﬁrming a connection be-
tween adipose tissue and CAM vascular network and also
showing active replication of vascular cells inside the graft
(Fig. 4E).
Finally, a RCAS avian retrovirus tagged with GFP was
injected into the vitellin anterior vein of chick embryos.
Fluorescent, RCAS-infected chick cells were present in the
wall of vessels attracted by the samples (Fig. 4F). The
presence of RCAS-infected cells inside adipose tissue
samples was conﬁrmed by immunohistochemistry using
an anti-GFP antibody (Fig. 4G).
Origin of the vessels inside adipose tissue. Experi-
ments with RCAS suggested the presence of chicken
vessels inside adipose tissue grafts. To determine the
chick or human origin of the vessels that developed in
adipose tissue, endothelial cells in sections of successfully
grafted adipose tissue were stained with an anti–human
CD34 antibody. The species speciﬁcity of this antibody
was conﬁrmed by the absence of staining of CAM vessels
distant from grafts (Fig. 5A). In contrast, vessels inside the
FIG. 2. Ratio of mRNA expression of angiogenesis genes in adipose tissue. Results are expressed as fold differences between SAT and VAT and
are the means of the data of mRNA abundance in whole adipose tissue from 10 obese patients of a set of genes involved in the regulation of
angiogenesis and that of ﬁve genes of adipocyte differentiation (adiponectin, fatty acid binding protein-4 [FABP-4], hormone-sensible lipase [HS
Lipase], leptin, and PPAR). MMP, matrix metallo proteinase; PDGF, platelet-derived growth factor; PLGF, placental growth factor; TGF,
transforming growth factor. Positive values indicate a higher expression in VAT than in SAT. The difference of mRNA expression between SAT
and VAT was considered signiﬁcant when fold difference was >2. This threshold is indicated by a dotted line. Details of the data are available in
the online appendix (supplementary Table).
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antibody (Fig. 5B). The presence of nucleated chick erythro-
cytes in the lumen of the stained vessels (Fig. 5B) indicated
that these vessels were functional. Furthermore, the detec-
tion of CD34
 human vessels budding from CD34
 CAM
vessels (Fig. 5C) showed that the interaction of adipose
tissue with CAM induced the recruitment of human endothe-
lial cells. Finally, in experiments performed with quail em-
bryos, double staining with anti-QH1 and anti-CD34
antibodies conﬁrmed the presence of avian endothelial cells
inside the adipose tissue vessels and the mobilization of
human endothelial cells into quail CAM bordering adipose
tissue samples (Fig. 5D and E). Furthermore, the double
staining evidenced chimeric vessels made up of endothelial
cells of both avian and human origin (Fig. 5E and F).
Comparison of the angiogenic response in SAT and
VAT. The angiogenic response of the CAM to adipose
tissue was not inﬂuenced by the origin of the samples: The
percentage of macroscopically detectable angiogenic re-
sponse was similar for SAT (38%, n  467) and VAT (40%,
n  446). Also, the percentage of positive angiogenic
responses assessed by angiography for samples from 11
patients was 60% for SAT (n  63) and 61% for VAT (n 
54). To conﬁrm this ﬁnding, we studied the kinetics of
angiogenesis induction in SAT and VAT. The time of
apparition of covered samples did not differ between
samples of the two origins: in both cases, it started on day
10 (48 h after graft) and increased up to day 15 (supple-
mentary Figure available in the online appendix). The
angiogenic stimulation did not correlate with the weight of
the samples in the range of 3–50 mg. The “dose-response”
proﬁle did not differ between SAT and VAT. Overall, these
ﬁndings are consistent with the similar abundance of
mRNAs of the main angiogenic factors in VAT and SAT.
Role of VEGF. VEGF inhibitors were used to determine
the role of VEGF, the main angiogenic growth factor, in
the angiogenic response induced by adipose tissue (Fig. 6).
First, PTK added at days 9 and 10 substantially inhibited
angiogenesis around almost all of the samples (n  8).
PTK also inhibited angiogenesis on the CAM, such that
vessels were absent from large areas as shown by angiog-
raphy (Fig. 6B). Neutralization of human VEGF with
bevacizumab added at days 9 and 10 strongly inhibited the
angiogenic response of the CAM to the adipose tissue
samples; it caused a large decrease of the vascular net-
work around the samples compared with vehicle (Fig. 6A)
but had no effect on the CAM vessel density (Fig. 6C). The
effect of bevacizumab did not differ between SAT and VAT
samples (Fig. 6D). These ﬁndings highlighted the major
role of VEGF in both SAT and VAT angiogenesis.
Relation with phenotype. We did not ﬁnd any direct
correlation between the angiogenic potency of adipose
tissue samples, measured as the percentage of covered
samples, and histological characteristics, such as adipo-
cyte area and the presence of inﬂammatory inﬁltrate in
adipose tissue before graft, either in SAT or in VAT.
No correlation was found between SAT and VAT angio-
genic responses and age, weight, or BMI. However, we
found a positive correlation between the SAT angiogenic
response and waist-to-hip ratio (r
2  0.243, P  0.0078).
A
C
B
D
FIG. 3. In vivo angiogenesis induced by adipose tissue on CAM. Adipose tissue samples were layered on the CAM on day 8 of incubation and were
observed between days 13 and 15. A: Macroscopic engulfment of adipose tissue sample. B: Normal angiographic aspect of CAM. C: Vascular
attraction by adipose tissue on angiography. D: Angiographic aspect of covered sample with strong angiogenic stimulation. (Please see
http://dx.doi.org/10.2337/db07-1812 for a high-quality digital representation of this ﬁgure.)
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FIG. 4. Connection between CAM vascular network and adipose tissue vessels. Viability of adipose tissue samples layered on the CAM was
assessed by hematoxylin-eosin coloration of adipose tissue samples layered on CAM. Successfully grafted samples showing an angiogenic
response had normal adipose tissue architecture (A), whereas adipose tissue degeneration was observed in samples without an angiogenic
response (B). C: Staining with Hypoxyprobe at day 15 (incubated for3ha t2 1 %O 2 after an intravenous injection) showed a weak staining at the
border between CAM and adipose tissue sample predominantly at the tip of the engulfment zone (see arrows) without staining inside the grafts.
D: Adipose tissue samples layered on CAM from days 8 to 15 were stained with an antibody speciﬁc for chick erythrocytes. E: BrdU inside the
samples was detected with an anti-BrdU antibody using samples that were collected 18 h after injection of BrdU in a CAM vein. An avian RCAS
retrovirus-GFP was injected into the vitellin anterior vein of chick embryos on day 3. Adipose tissue samples were layered on the CAM on day
8. F: On day 15, ﬂuorescence was observed in vessels formed around the samples, indicating that avian vessels had been the site of active
angiogenesis. G: RCAS-GFP was detected in ﬁxed adipose tissue samples stained with an anti-GFP antibody, indicating that cells of avian origin
had inﬁltrated the vessels undergoing active angiogenesis inside the adipose tissue graft. (Please see http://dx.doi.org/10.2337/db07-1812 for a
high-quality digital representation of this ﬁgure.)
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mean area of visceral adipocytes and with serum insulin
levels and the HOMA index measured in the 22 nondia-
betic patients (Fig. 7). There was no correlation with
systolic blood pressure and other markers of the meta-
bolic syndrome: triglyceride concentrations and HDL cho-
lesterol concentrations (data not shown). In multivariate
analysis, only mean area of visceral adipocytes and serum
insulin level remained signiﬁcantly associated with SAT
angiogenesis. In contrast, there was no correlation be-
tween the VAT angiogenic response and markers of the
metabolic syndrome, except for a weak correlation with
waist-to-hip ratio (Fig. 7).
DISCUSSION
There has been little work on the regulation of adipose
tissue angiogenesis in obese subjects, although evidence
A
50 µm
D
100 µm
C
100 µm 50 µm
F
B
100 µm 50 µm
E
FIG. 5. Recruitment of human and avian endothelial cells. A–C: Adipose tissue samples layered on chick CAM from days 8 to 15 were stained with
hematoxylin-eosin and an anti–human CD34 antibody. The arrows point to a CD34
 vessel of the CAM (A) and to a CD34
 vessel in adipose tissue (B).
B: See the nucleated chick erythrocytes inside the CD34
 vessels around adipocytes of successfully grafted adipose tissue. C: A CD34
 vessel buds from
a CAM, CD34
 vessel. D–F: Adipose tissue samples were layered on quail CAM for double staining of endothelial cells with anti–human CD34 antibody
(in brown) and anti–quail-QH1 (in green) antibody that stains quail endothelial cells but does not cross-react with human endothelial cells. See the
coexistence of human and quail vessels within the adipose tissue (D and E) and the presence (arrows) of both quail and human endothelial cells in the
same vessels (E and F). (Please see http://dx.doi.org/10.2337/db07-1812 for a high-quality digital representation of this ﬁgure.)
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tissue. Our study shows that adipose tissue from obese
adult subjects grafted on CAM was able to induce angio-
genesis with recruitment of vascular cells of both human
and host (avian) origin. Although the expression of several
angiogenic genes differed slightly between SAT and VAT,
the expression of the main angiogenic factors, and notably
VEGF, was similar in SAT and VAT. SAT and VAT also had
similar angiogenic potencies on CAM, and inhibition of
VEGF strongly inhibited angiogenesis in both tissues.
Adipose tissue is highly vascularized (2,3,5,9), and many
angiogenic factors are secreted by adipose tissue, includ-
ing VEGF, hepatocyte growth factor, placental growth
factor (PlGF), angiopoietins, FGFs, TNF-, PAI-1, and
metalloproteases (2,8,9,18,32,33). Adipose tissue contains
mature adipocytes and many other cell types known as the
stromavascular fraction, which includes preadipocytes,
endothelial cells, inﬂammatory cells, and progenitor cells
(35). The respective contributions of stromavascular frac-
tion and mature adipocytes to the secretion of angiogenic
factors are unclear (16,18,32,33,36,37). Our preliminary
results suggest that VEGF, one main angiogenic factor,
was expressed by both stromavascular fraction cells and
mature adipocytes, as described in both animals and
humans by some authors (2,36,38). Most in vivo studies of
adipose tissue angiogenesis focused on stromavascular
fraction cells isolated from adipose tissue (12,15,17). Few
studies have tested the angiogenic properties of whole
intact adipose tissue (13,14,25,39). Early studies described
a stimulation of angiogenesis by adipose tissue in animal
models, such as grafts of rabbit adipose tissue onto cornea
(13) or onto the brain surface (14). A more recent study
showed de novo formation of vessels from human adipose
tissue embedded in ﬁbrin thrombin clot (25). The adipose
tissue samples that we obtained from obese subjects
induced a powerful angiogenic response when layered on
CAM, a well-known and robust model of angiogenesis (27).
We observed successful connection of adipose tissue and
CAM vascularization in most of the samples.
In a model of subcutaneous injection of 3T3 preadipo-
cytes in nude mice, it was shown by ﬂuorescent staining
that the vessels induced by the grafted fat pads originate
only from the host, not from the adipose cells (32). Here,
we show that after grafting of human adipose tissue on
CAM, the new vessels, both inside and around the grafts,
were of both avian and human origin. These ﬁndings
demonstrate that when the blood supply becomes deﬁ-
cient, human adult whole adipose tissue can induce angio-
genesis from its own cells and also recruit distant
endothelial cells. It would be interesting to determine the
nature of the human endothelial precursors because adi-
pose stem cells can differentiate into endothelial cells
(10,12).
To our knowledge, little is known about vessel density
with respect to adipose tissue localization (5), and no
study has compared the angiogenic potencies of SAT and
VAT in humans. In rabbit, corneal neovascularization
induced by rabbit VAT and SAT were similar in both rate
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FIG. 6. Effect of VEGF inhibitors on angiogenesis associated with adipose tissue. SAT (n  38) and VAT (n  32) samples were layered on CAM
on day 8. Angiographic observation was performed on day 15. Adipose tissue samples were incubated on days 9 and 10 with: vehicle (A), resulting
in a typical angiogenic response with engulfment; 200 mol/l PTK (B), resulting in inhibition of the angiogenic response both around the sample
and on the CAM; or 300 g/ml bevacizumab (C), resulting in inhibition of the angiogenic response around the sample. D: The percentages of
covered SAT and VAT samples in controls incubated with vehicle (CT, ) and samples incubated with bevacizumab (BV, f). Bar graphs are 95%
CI. *P < 0.05, **P < 0.01. (Please see http://dx.doi.org/10.2337/db07-1812 for a high-quality digital representation of this ﬁgure.)
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ties in VAT and SAT from obese human subjects did not
differ after adjustment for adipocyte densities. Moreover,
SAT and VAT had the same angiogenic potency on CAM.
Our results are supported by the similar expression of the
major angiogenic factors in the two tissues, in contrast
with observations in animal models, which indicate higher
expression of VEGF in VAT than in SAT (18,19,36). These
converging results suggest that despite metabolic differ-
ences between VAT and SAT (33), the main factors of
angiogenesis regulation are conserved in human adipose
tissue at different sites to maintain appropriate vessel
density for the number of adipocytes.
The angiogenic property of adipose tissue was not
correlated with BMI or adipocyte size. This may be be-
cause all of the patients had long-term, stable obesity. It
has been suggested that the expression of angiogenic
factors is related to variations of weight rather than to the
absolute weight (2,20,40). Another explanation could be
that, whereas both hyperplasia and hypertrophy of adi-
pose tissue inﬂuence BMI, only hyperplasia is linked to
adipose tissue angiogenesis (39).
Hypoxia and inﬂammation strongly promote angiogene-
sis (2,3,25,32). It was shown in mice that oxygen supply is
decreased in hypertrophic adipose tissue (41), and expres-
sion and macrophage density of cytokines in adipose
tissue are increased in obesity (37,42). However, we did
not observe stigma of hypoxia in the core of successful
grafts, although active angiogenesis was present. Angio-
genic potency of adipose tissue was not correlated with
inﬂammatory inﬁltrate. Although we found that the inﬂam-
matory cell density assessed before graft was higher in
VAT than in SAT, as previously described (42), angiogen-
esis did not differ between the two sites in our study.
An unexpected and interesting ﬁnding was that angio-
genic potency of SAT correlated with stigma of insulin
resistance, including waist-to-hip ratio, visceral adipocyte
hypertrophy, insulin levels, and HOMA index, in nondia-
betic patients (43). Insulin resistance and visceral adipos-
ity are linked (43), and we found an association between
VAT adipocyte area and insulin resistance in our patients
(44). In patients with abdominal obesity, stimulation of
SAT angiogenesis associated with insulin resistance may
promote SAT hyperplasia, thus enhancing the storage
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SAT against metabolic disturbances is now well demon-
strated (46). Insulin has angiogenic properties, in part
through VEGF stimulation (3,38,47,48), notably in adipose
tissue (49). Given the greater insulin sensitivity of SAT
than VAT (33,35), one can assume that insulin may directly
enhance angiogenesis in SAT, in parallel to adipogenesis.
However, we cannot rule out the involvement of other
factors associated with both insulin resistance and angio-
genesis, such as resistin and visfatin (22,50,51).
VEGF inhibitors strongly inhibited angiogenesis of both
SAT and VAT layered on CAM, clearly demonstrating a
major role for VEGF in angiogenesis associated with
adipose tissue. However, inhibition of angiogenesis was
observed when VEGF inhibitors were added at day 9 to 10,
but later on, other factors may be involved in the angio-
genic process. VEGF inhibitors are used clinically for the
treatment of cancers and retinal vascular proliferative
diseases (28), but their effects on adipose tissue of treated
patients have not been studied. In animal studies, inhibi-
tion of VEGF (8,36,40) or PlGF (24) reduced not only
adipose tissue angiogenesis but also adipose tissue expan-
sion. Better knowledge of angiogenesis regulation in adi-
pose tissue may allow angiogenesis inhibition to be
focused on adipose tissue.
Our study has several limitations. First, we used the
model of CAM to study angiogenesis, and the results need
to be conﬁrmed in vivo in murine models and in vitro using
human endothelial cells, because species-speciﬁc re-
sponses may exist (52). We only investigated severely
obese patients, and it would be interesting to compare
angiogenesis of adipose tissue from lean and obese sub-
jects. Furthermore, comorbidities, notably diabetes, and
medications taken by the patients could have inﬂuenced
angiogenesis, but the number of patients included in this
study did not allow subgroup analyses.
In conclusion, we have shown that human adipose
tissue from severely obese adults is able to induce angio-
genesis involving recruitment of its own endothelial cells.
There was no difference in the angiogenic potency of SAT
and VAT. VEGF, which was expressed at similar levels in
SAT and VAT, seemed to play a major role in adipose
tissue angiogenesis. Further studies are needed to docu-
ment the link between VEGF expression, insulin resis-
tance, adipogenesis, and angiogenesis.
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